


Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect







Coronavirus disease 2019 (COVID 19) and Malaria Have anti glycoprotein antibodies a role?



ARTICLE INFO

Keywords: Coronavirus-2 Mortality Malaria infection Cross reactivity Protective factor

To the dear Editor,

Italian people are actually living a severe crisis due to a Coronavirus disease 2019 (COVID-19). The North of Italy, is particularly affected with a great proportion of severe acute respiratory syndrome. In the northern Italian regions the presence of African people, usually employed in iron-steel factories and agricultural works, is high. Now, among the people recovered in the hospitals with moderate or severe COVID-19, the presence of black people is very low. According to the data of Italian Superior Institute of Health, in Bergamo, one of the cities of Lombardia mostly affect, the black people with moderate to severe COVID-19 are about 1,6% of COVID-19 patients [1]. These data are real because the Italian health system is free and allows all people to access to treatments. So we think that are not underestimation of the number of asymptomatic people of black people affected by COVID-19. We also noted that in central African countries the distribution of COVD-19 is nil or very low as referred by Napoli and Nioi in their work [2]. Why? Because the black people who live in Italy are young and it is known that COVID-19 is more frequent in old people with comorbidities. Or it can be due to a different genetic susceptibility of African people as occur in women and men the latter having higher range of severity and mortality [3,4]. However it is known that in African-Americans the severity of COVID-19 is high so, we think that the theory of immune genetic factors does not completely explain the answer. In addition according to the data of WHO the dashboard of the pandemic in the most African countries is very low and in some nations the total cases of COVID-19 are less than 10 units [5] and nowadays experts still do not know how so few cases of the new virus had been reported despite China, where the virus originated, being the continent's top trading partner. It can be due to a lack of detection or the monitoring efforts are weak [6]. In the African continent malaria is one of the diseases which cause significant morbidity and mortality. We speculate that anti-malarial immunity may also play a role. We know that individuals who have had malaria or asymptomatic malaria have antibodies (IgG) to Plasmodium specific antigens. These antibodies are directed to Glycosylphosphatidylinositol (GPI), the anchor molecules of some membrane proteins of Plasmodium species. Although in malaria previous infection is not fully protective, as evidenced by repeated infections experienced

by people living in endemic areas, clinical presentation among "such immune" people, is less severe than in non-immune people [7]. In addition children who, usually have antibodies to different viruses or bacteria are known to be protected towards COVID-19 [8]. GPI is a phospholipid which can activate leukocytes, trigger the release of proinflammatory cytokines and induce the expression of adhesion molecules via Toll like receptors 2 and 4. Anti GPI antibodies may neutralize the toxic effect of Plasmodium GPI. Also coronavirus 19 presents different glycoproteins (GPs):membrane GPs, spike GPs and GPs that have acetyl esterase and hemagglutination properties .These GPs could be recognized by the antibodies produced in malaria and could protect by virus infection or induced a milder disease[9]. In addition COVID- 19 and malaria present other similarities. Blood group 0 patients are associated with a low risk of malaria infection [10] probably due to mimicry of A or B antigens by infectious agents [10]. The same occurs in COVID-19. The natural anti histo-blood group antibodies may play a favorable role in antiviral immunity since the viruses may carry ABH structures in their envelope glycoproteins as previously demonstrated for other coronavirus [11]. The second similarity is that the 2 diseases respond to anti-malarials. For some Authors these drugs could represent a sort of chemoprophylaxis against COVID-19 in African countries because they promote also in COVID- 19 a virus negative conversion, shortening of the disease course and improving lung imaging findings as seen both in vitro and in vivo [2,12].

Funding

This research received no external funding.

Conflicts of interest

The authors declare no conflict of interest.

CRediT authorship contribution statement

Aurora Parodi: Conceptualization, Writing - original draft, Writing - review & editing. **Emanuele Cozzani:** Writing - original draft, Writing - review & editing.

https://doi.org/10.1016/j.mehy.2020.110036 Received 18 May 2020; Received in revised form 12 June 2020; Accepted 22 June 2020 0306-9877/ © 2020 Published by Elsevier Ltd.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.110036.

References

- [1] Superior Institute of Health [ISS] April 2020.
- [2] Napoli PE, Nioi M. Global spread of coronavirus disease 2019 and malaria: an epidemiological paradox in the early stage of a pandemic. J Clin Med 2020;16(9):1138.
- [3] Napoli PE, Nioi M, d'Aloja E, Fossarello M. The ocular surface and the coronavirus disease 2019: does a dual 'ocular route' exist? J Clin Med. 2020;9:E1269.
- [4] Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21:E3474.
- WHO Coronavirus Disease 2019 (COVID-19) Situation Report—72. [(accessed on 31 May 2020)];2020 Available online: https://reliefweb.int/sites/reliefweb.int/files/ resources/20200328-sitrep-68-covid-19.pdf.
- [6] Napoli PE, Nioi M, d'Aloja E, Fossarello M. Safety Recommendations and Medical Liability in Ocular Surgery during the COVID-19 Pandemic: An Unsolved Dilemma.

J Clin Med. May 9;9:E1403.d.

- [7] Mendonça VR, Barral-Netto M. Immunoregulation in human malaria: the challenge of understanding asymptomatic infection. Mem Inst Oswaldo Cruz 2015;110:945–55.
- [8] Okay RA, Sahin AR, Aguinada RA, Tasdogan AM. Why are children less affected by COVID-19? Could there be an overlooked bacterial co-infection? EJMO 2020;4:104–5.
- [9] Gomes LR, Martins YC, Ferreira-da-Cruz MF, Daniel-Ribeiro CT. Autoimmunity, phospholipid-reacting antibodies and malaria immunity. Lupus 2014;23:1295–8.
- [10] Afoakwah R, Aubyn E, Prah J, Nwaefuna EK, Boampong JN. Relative susceptibilities of ABO blood groups to plasmodium falciparum malaria in Ghana. Adv Hematol 2016:5368793.
- [11] Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008;18:1085–93.
- [12] Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;177:104762.

Aurora Parodi, Emanuele Cozzani*

Dermatologic Unit, University of Genoa, DiSSal, Ospedale-Policlinico San Martino, IRCCS, Largo R. Benzi 10, 16132 Genova, Italy E-mail address: Emanuele.cozzani@unige.it (E. Cozzani).

^{*} Corresponding author.